ACNP - Italian Periodicals Catalogue

AAAAAA

ITA
ENG

Results: 1-25 | 26-42 |

Results: 26-42/42

AVAILABILITY OF ANTICANCER DRUGS IN THE UNITED-STATES, EUROPE, AND JAPAN FROM 1960 THROUGH 1991

Authors: BROWN JS BIENZTADMOR B LASAGNA L

Citation: Js. Brown et al., AVAILABILITY OF ANTICANCER DRUGS IN THE UNITED-STATES, EUROPE, AND JAPAN FROM 1960 THROUGH 1991, Clinical pharmacology and therapeutics, 58(3), 1995, pp. 243-256

DRUG SAFETY DISCONTINUATIONS IN THE UNITED-KINGDOM, THE UNITED-STATES, AND SPAIN FROM 1974 THROUGH 1993 - A REGULATORY PERSPECTIVE

Authors: BAKKE OM MANOCCHIA M DEABAJO F KAITIN KI LASAGNA L

Citation: Om. Bakke et al., DRUG SAFETY DISCONTINUATIONS IN THE UNITED-KINGDOM, THE UNITED-STATES, AND SPAIN FROM 1974 THROUGH 1993 - A REGULATORY PERSPECTIVE, Clinical pharmacology and therapeutics, 58(1), 1995, pp. 108-117

AN ANALYSIS OF REGULATORY REVIEW TIMES OF SUPPLEMENTAL INDICATIONS FOR ALREADY APPROVED DRUGS

Authors: DIMASI JA BROWN JS LASAGNA L

Citation: Ja. Dimasi et al., AN ANALYSIS OF REGULATORY REVIEW TIMES OF SUPPLEMENTAL INDICATIONS FOR ALREADY APPROVED DRUGS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 195-195

DRUG SAFETY DISCONTINUATIONS - A COMPARISON OF UK, US, AND SPAIN 1974-93

Authors: BAKKE OM MANOCCHIA M DEABAJO F KAITIN KI LASAGNA L

Citation: Om. Bakke et al., DRUG SAFETY DISCONTINUATIONS - A COMPARISON OF UK, US, AND SPAIN 1974-93, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 195-195

INTRODUCTION

Authors: LASAGNA L

Citation: L. Lasagna, INTRODUCTION, PharmacoEconomics, 6, 1994, pp. 1-2

CLOSING COMMENTS

Authors: LASAGNA L

Citation: L. Lasagna, CLOSING COMMENTS, PharmacoEconomics, 6, 1994, pp. 85-87

FOREWORD

Authors: SHULMAN S LASAGNA L

Citation: S. Shulman et L. Lasagna, FOREWORD, PharmacoEconomics, 6, 1994, pp. 180000007-180000008

DETERMINING APPROPRIATE REIMBURSEMENT FOR PRESCRIPTION DRUGS - OFF LABEL USES AND INVESTIGATIONAL THERAPIES

Authors: RAIFORD DS SHULMAN SR LASAGNA L

Citation: Ds. Raiford et al., DETERMINING APPROPRIATE REIMBURSEMENT FOR PRESCRIPTION DRUGS - OFF LABEL USES AND INVESTIGATIONAL THERAPIES, Food and drug law journal, 49(1), 1994, pp. 37-76

OVER-THE-COUNTER NIACIN

Authors: LASAGNA L

Citation: L. Lasagna, OVER-THE-COUNTER NIACIN, JAMA, the journal of the American Medical Association, 271(9), 1994, pp. 709-710

A WHITE PAPER ON THE APPROPRIATENESS OF PROPOSALS BY THE FDA TO MODIFY LABELING OF BENZODIAZEPINE SEDATIVE-HYPNOTICS

Authors: LASAGNA L SHADER RI

Citation: L. Lasagna et Ri. Shader, A WHITE PAPER ON THE APPROPRIATENESS OF PROPOSALS BY THE FDA TO MODIFY LABELING OF BENZODIAZEPINE SEDATIVE-HYPNOTICS, Journal of clinical pharmacology, 34(8), 1994, pp. 812-815

THE NEW DRUG APPROVALS OF 1990, 1991, AND 1992 - TRENDS IN DRUG DEVELOPMENT

Authors: KAITIN KI MANOCCHIA M SEIBRING M LASAGNA L

Citation: Ki. Kaitin et al., THE NEW DRUG APPROVALS OF 1990, 1991, AND 1992 - TRENDS IN DRUG DEVELOPMENT, Journal of clinical pharmacology, 34(2), 1994, pp. 120-127

ROLE OF L-CARNITINE IN TREATING RENAL DIALYSIS PATIENTS

Authors: AHMAD S BRASS EP HOPPEL C KOPPLE JD LASAGNA L LUNDIN AP SCHREINER GE SHERIDAN MJ

Citation: S. Ahmad et al., ROLE OF L-CARNITINE IN TREATING RENAL DIALYSIS PATIENTS, Dialysis & transplantation, 23(4), 1994, pp. 177

NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992

Authors: DIMASI JA SEIBRING MA LASAGNA L

Citation: Ja. Dimasi et al., NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992, Clinical pharmacology and therapeutics, 55(6), 1994, pp. 609-622

COMPARISON OF AVAILABILITY OF CANCER DRUGS IN THE US, EUROPE AND JAPAN

Authors: BROWN J BIENZTADMOR B LASAGNA L

Citation: J. Brown et al., COMPARISON OF AVAILABILITY OF CANCER DRUGS IN THE US, EUROPE AND JAPAN, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 158-158

12-MONTH TOXICITY STUDIES - WHAT DO WE LEARN

Authors: KAITIN K BROWN J LASAGNA L

Citation: K. Kaitin et al., 12-MONTH TOXICITY STUDIES - WHAT DO WE LEARN, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 159-159

THE ROLE OF THE RESEARCH-BASED PHARMACEUTICAL-INDUSTRY IN MEDICAL PROGRESS IN THE UNITED-STATES

Authors: KAITIN KI BRYANT NR LASAGNA L

Citation: Ki. Kaitin et al., THE ROLE OF THE RESEARCH-BASED PHARMACEUTICAL-INDUSTRY IN MEDICAL PROGRESS IN THE UNITED-STATES, Journal of clinical pharmacology, 33(5), 1993, pp. 412-417

PRIMUM-NON-NOCERE

Authors: LASAGNA L

Citation: L. Lasagna, PRIMUM-NON-NOCERE, Clinical pharmacology and therapeutics, 54(5), 1993, pp. 584-584

Risultati: 1-25 | 26-42 |